drugset / Trial / NCT00322309

Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects

NCT00322309

Phase 2 Completed 24 enrolled Boston University
RandomizedParallel-groupDouble-blindTreatment

Summary

This research study is being done to look at the safety of the medication Mirtazapine (Remeron) in people who have cocaine dependence and depression. Hypotheses I. Cocaine usage will be less in the mirtazapine treatment group (MG) than in the control group (CG). II. A greater increase in Clinician Global Impression (CGI) score will be observed in the MG than in the CG. Secondary Hypotheses: I. A greater decrease in Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores will be observed in the MG than in the CG. II. A greater decrease in HIV risk behaviors will be observed in the MG than in the CG. III. A greater improvement in sleep structure will be observed in the MG than in the CG. IV. The proportion of subjects experiencing severe adverse drug reactions that necessitate termination from the study by one of the study clinicians will not differ between the MG and CG. V. Retention will be greater in MG than in CG.

Timeline

Start
2005-09
Primary completion
2009-07
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 45 mg